Elimination of C1498/B7-2 dominated by CD8+ T cells and resistance to C1498/B7-1-mediated by NK cells alone
| Depleted cells . | No. tumor progressors/injected mice (%)* . | |
|---|---|---|
| C1498/B7-2 (106) . | C1498/B7-1 (105) . | |
| None | 0/8 (0) | 5/11 (45) |
| CD4 | 0/8 (0) | 2/5 (40) |
| CD8 | 8/8 (100)† | 5/12 (42) |
| CD4 + CD8 | 8/8 (100)† | Not done |
| NK1.1 | 0/8 (0) | 11/11 (100)‡ |
| Depleted cells . | No. tumor progressors/injected mice (%)* . | |
|---|---|---|
| C1498/B7-2 (106) . | C1498/B7-1 (105) . | |
| None | 0/8 (0) | 5/11 (45) |
| CD4 | 0/8 (0) | 2/5 (40) |
| CD8 | 8/8 (100)† | 5/12 (42) |
| CD4 + CD8 | 8/8 (100)† | Not done |
| NK1.1 | 0/8 (0) | 11/11 (100)‡ |
Percentage of mice that died or were killed because of progressive tumor growth after subcutaneous injection with 1 × 106 C1498/B7-2 or 1 × 105 C1498/B7-1 tumor cells. Data from two independent experiments were pooled.
Significantly different from the None, CD4, and NK1.1-depleted groups (Fischer exact test; P < .001).
Significantly different from the None, CD4, and CD8-depleted groups (Fischer exact test; P < .02).